Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors

British Journal of Pharmacology

Volumn 126, Issue 5, 1999, Pages 1246-1252

  Daeffler, Laurent ^a   Schmidlin, Fabien ^a   Gies, Jean Pierre ^a   Landry, Yves ^a  

^a INSERM   (France)

Author keywords

G protein; GPAnt 2; GppNHp; Inverse agonism; Mastoparan; Muscarinic M2 receptors; Pirenzepine

Indexed keywords

ATROPINE; CARBACHOL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; MASTOPARAN; METHYLSCOPOLAMINE; MUSCARINIC M2 RECEPTOR; OTENZEPAD; OXOTREMORINE M; PIRENZEPINE; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; HEART ATRIUM; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SARCOLEMMA; SWINE;

EID: 0033012583     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702407     Document Type: Article

References (37)

1. 35S]-GTPγS binding. Br. J. Pharmacol., 119, 6P.
2. BERRIE, C.P., BIRDSALL, N.J.M., BURGEN, A.S.V. & HULME, E.C. (1979). Guanine nucleotides modulate muscarinic receptor binding in the heart. Biochem. Biophys. Res. Commun., 87, 1000-1005.
3. BIRDSALL, N.J.M., BURGEN, A.S.V. & HULME, E.C. (1978). The binding of agonist to brain muscarinic receptors. Mol. Pharmacol., 14, 723-736.
4. BRADFORD, M.M. (1976). A rapid and sensitive method for a quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem., 72, 248-254.
5. BURGISSER, E., DE LEAN, A. & LEFKOWITZ, R.J. (1982). Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc. Natl. Acad. Sci. U.S.A., 79, 1732-1736.
6. CASSEL, D. & SELIUGER, Z. (1976). Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim. Biophys. Acta, 452, 538-551.
7. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3118.
8. COSTA, T. & HERTZ, A. (1989). Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins? Proc. Natl. Acad. Sci. U.S.A., 86, 7321-7325.
9. COSTA, T., OGINO, Y., MUNSON, P.J., ONGUN ONARAN, H. & RODBARD, D. (1992). Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol., 41, 549-560.
10. FLEMING, W.W., WESTFALL, D.P., DE LA LANDE, I.S. & JELLETT, L.B. (1972). Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J. Pharmacol. Exp. Ther., 181, 339-345.
11. FREEDMAN, S.B., DAWSON, G.R., IVERSEN, L.L., BAKER, R. & HARGREAVES, R.J. (1993). The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. Life Sci., 52, 489-495.
12. FREEDMAN, S.B., HARLEY, E.A. & IVERSEN, L.L. (1988). Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br. J. Pharmacol., 93, 437-445.
13. GIES, J.P., BERTRAND, C., VANDERHEYDEN, P., WAELDELE, G., DUMONT, P., PAULI, G. & LANDRY, Y. (1989). Characterization of muscarinic receptors in human, guinea pig and rat lung. J. Pharmacol. Exp. Ther., 250, 309-315.
14. GILMAN, A.G. (1987). G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem., 56, 615-649.
15. HAMMER, R., BERRIE, C.P., BIRDSALL, N.J.M., BURGEN, A.S.V. & HULME, E.C. (1980). Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature, 283, 90-94.
16. HIGASHIJIMA, T., UZU, S., NAKAJIMA, T. & ROSS, E.M. (1988). Mastoparan, a peptide toxin from wasp venom, mimics receptor by activating GTP-binding proteins (G proteins). J. Biol. Chem., 263, 6491-6494.
17. - ions. Eur. J. Pharmacol., 172, 155-163.
18. HILF, G. & JAKOBS, K.H. (1992). Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur. J. Pharmacol., 225, 245-252.
19. HOSEY, M.M. (1982). Regulation of antagonist binding to cardiac muscarinic receptors. Biochem. Biophys. Res. Commun., 107, 314-321.
20. HULME, E.C., BERRIE, C.P., BIRDSALL, N.J.M. & BURGEN, A.S.V. (1981). Two populations of binding sites for muscarinic antagonists in the rat heart. Eur. J. Pharmacol., 73, 137-142.
21. HULME, E.C., BIRDSALL, N.J.M., BURGEN, A.S.V. & METHA, P. (1978). The binding of antagonists to brain muscarinic receptors. Mol. Pharmacol., 14, 737-750.
22. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett., 377, 275-279.
23. KENAKIN, T. (1997). Agonist-specific receptor conformations. Trends Pharmacol. Sci., 18, 416-417.
24. LEFF, P. (1995). The two-state model of receptor activation. Trends Pharmacol. Sci., 16, 89-97.
25. LEFKOWITZ, R.J., MULLIKIN, D. & CARON, M.G. (1976). Regulation of beta-adrenergic receptors by guanyl-5′-yl imidodiphosphate and other purine nucleotides. J. Biol. Chem., 251, 4686-4692.
26. MAGUIRE, M.E., VAN ARSDALE, P.M. & GILMAN, A.G. (1976). An agonist-specific effect of guanine nucleotides on binding to the beta adrenergic receptor. Mol. Pharmacol., 12, 335-339.
27. MARTIN, M.W., SMITH, M.M. & HARDEN, T.K. (1984). Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart. J. Pharmacol. Exp. Ther., 230, 424-430.
28. MILLIGAN, G., BOND, R.A. & LEE, M. (1995). Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci., 16, 10-13.
29. MOUSLI, M., BUEB, J.-L., BRONNER, C., ROUOT, B. & LANDRY, Y. (1990). G proteins activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol. Sci., 11, 358-362.
30. MUKAI, H., MUNEKKATA, E. & HIGASHIJIMA, T. (1992). G protein antagonists. J. Biol. Chem., 267, 16237-16243.
31. MUNSON, J. & RODBARD, D. (1980). Ligand: a versatile computerized approach to characterization of ligand-binding systems. Anal. Biochem., 107, 220-239.
32. 1A receptors by the inverse agonist, spiperone but not by the neutral antagonist, WAY 100,635. Br. J. Pharmacol., 120, 737-739.
33. PETERSON, G.L. & SCHIMERLIK, M.I. (1984). Large scale preparation and characterization of membrane-bound and detergent-solubilized muscarinic acetylcholine receptor from pig atria. Prep. Biochem., 14, 33-74.
34. + and guanyl nucleotides. J. Biol. Chem., 255, 820-823.
35. 4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes. Neurochem. Res., 70, 669-674.
36. TUCEK, S. (1997). Is the R and R* dichotomy real? Trends Pharmacol. Sci., 18, 414-416.
37. VAN GELDEREN, J.G., DAEFFLER, L., SCHERRER, D., MOUSLI, M., LANDRY, Y. & GIES, J.P. (1996). M2-muscarinic receptors: how does ligand binding affinity relate to intrinsic activity? J. Receptor Signal Transd. Res., 16, 135-148.